Shambavi Richard, MD

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

CAR T-cell therapy and bispecific antibodies for T-cell redirection are 2 recent immune strategies developed in the treatment of multiple melanoma.

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Shambavi Richard, MD, highlights the rapidly evolving armamentarium ​in multiple myeloma.

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma.